NASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free XNCR Stock Alerts $18.95 -0.12 (-0.63%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$18.72▼$19.1650-Day Range$18.65▼$26.5252-Week Range$16.49▼$28.96Volume466,377 shsAverage Volume694,661 shsMarket Capitalization$1.16 billionP/E RatioN/ADividend YieldN/APrice Target$36.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Xencor alerts: Email Address Xencor MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside90.0% Upside$36.00 Price TargetShort InterestBearish9.72% of Shares Sold ShortDividend StrengthN/ASustainability-2.24Upright™ Environmental ScoreNews Sentiment-0.23Based on 6 Articles This WeekInsider TradingSelling Shares$2.15 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.25) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.66 out of 5 starsMedical Sector234th out of 918 stocksPharmaceutical Preparations Industry91st out of 402 stocks 4.4 Analyst's Opinion Consensus RatingXencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXencor has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.72% of the outstanding shares of Xencor have been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Xencor has recently increased by 6.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXencor has received a 53.56% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Tafasitamab", and "Ravulizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Xencor is -2.24. Previous Next 1.0 News and Social Media Coverage News SentimentXencor has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Xencor this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Xencor to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,152,417.00 in company stock.Percentage Held by InsidersOnly 4.97% of the stock of Xencor is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.25) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -9.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -9.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Xencor Stock (NASDAQ:XNCR)Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More XNCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XNCR Stock News HeadlinesApril 17, 2024 | americanbankingnews.comXencor (NASDAQ:XNCR) Price Target Lowered to $38.00 at BTIG ResearchApril 17, 2024 | americanbankingnews.comXencor (NASDAQ:XNCR) Stock Price Down 4.5% Following Analyst DowngradeApril 18, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.April 16, 2024 | markets.businessinsider.comAnalyst Scoreboard: 6 Ratings For XencorApril 11, 2024 | uk.investing.comXencor names Bart Cornelissen as new CFOApril 10, 2024 | markets.businessinsider.comXencor Appoints Bart Cornelissen As CFOApril 9, 2024 | marketwatch.comXencor Names Bart Cornelissen Chief Financial OfficerApril 9, 2024 | finance.yahoo.comXencor Appoints Bart Cornelissen as Chief Financial OfficerApril 18, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.April 9, 2024 | businesswire.comXencor Appoints Bart Cornelissen as Chief Financial OfficerApril 9, 2024 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 16, 2024 | finance.yahoo.comXNCR Apr 2024 30.000 callMarch 9, 2024 | finance.yahoo.comXNCR May 2024 22.500 putMarch 7, 2024 | finance.yahoo.comInsider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR)March 1, 2024 | markets.businessinsider.comXencor’s Strategic Focus and Pipeline Progress Affirm Buy RatingMarch 1, 2024 | msn.comPiper Sandler Downgrades Xencor (XNCR)February 29, 2024 | morningstar.comXencor Inc XNCRFebruary 29, 2024 | finance.yahoo.comXencor Full Year 2023 Earnings: Misses ExpectationsFebruary 28, 2024 | seekingalpha.comXencor Q4 2023 Earnings PreviewFebruary 28, 2024 | finance.yahoo.comXencor to Present at Upcoming Investor ConferencesFebruary 28, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On XencorFebruary 28, 2024 | msn.comXencor slips as Piper cuts citing patient death in cancer studyFebruary 28, 2024 | markets.businessinsider.comXencor (XNCR) Gets a Buy from TD CowenFebruary 28, 2024 | finance.yahoo.comXencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | sfgate.comXencor: Q4 Earnings SnapshotFebruary 27, 2024 | finance.yahoo.comXencor Inc (XNCR) Reports Mixed Financial Results for Q4 and Full Year 2023February 27, 2024 | businesswire.comXencor Reports Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/18/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XNCR CUSIPN/A CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$36.00 High Stock Price Target$50.00 Low Stock Price Target$24.00 Potential Upside/Downside+89.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,090,000.00 Net Margins-74.90% Pretax Margin-71.55% Return on Equity-18.67% Return on Assets-15.23% Debt Debt-to-Equity Ratio0.02 Current Ratio7.36 Quick Ratio7.36 Sales & Book Value Annual Sales$168.34 million Price / Sales6.90 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book1.73Miscellaneous Outstanding Shares61,120,000Free Float58,082,000Market Cap$1.16 billion OptionableOptionable Beta0.76 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Bassil I. Dahiyat Ph.D. (Age 54)Co-Founder, CEO, President & Director Comp: $1.08MMr. John J. Kuch (Age 65)Senior VP & CFO Comp: $660.75kDr. John R. Desjarlais Ph.D. (Age 60)Executive VP of Research & Chief Scientific Officer Comp: $711.45kMs. Celia E. Eckert J.D. (Age 51)Senior VP, General Counsel & Corporate Secretary Comp: $646.25kDr. Nancy Valente M.D. (Age 65)Executive VP & Chief Development Officer Comp: $28.16kMr. Charles LilesAssociate Director and Head of Corporate Communications & Investor RelationsMs. Jennifer SandozVice President of Human ResourcesDr. Jeremy Grunstein Ph.D.Senior Vice President of Business DevelopmentMr. Kirk Rosemark RAC (Age 59)Senior Vice President of Regulatory Affairs & Quality Assurance Mr. Eric P. KowackSenior Vice President of Program Leadership & Alliance ManagementMore ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULCollegium PharmaceuticalNASDAQ:COLLProthenaNASDAQ:PRTAMirum PharmaceuticalsNASDAQ:MIRMAbCellera BiologicsNASDAQ:ABCLView All CompetitorsInsiders & InstitutionsDiversified Trust CoBought 563 shares on 4/18/2024Ownership: 0.021%Los Angeles Capital Management LLCBought 10,347 shares on 4/5/2024Ownership: 0.017%GAMMA Investing LLCBought 1,316 shares on 4/5/2024Ownership: 0.004%PNC Financial Services Group Inc.Sold 871 shares on 3/22/2024Ownership: 0.005%Vanguard Group Inc.Bought 115,886 shares on 3/11/2024Ownership: 11.072%View All Insider TransactionsView All Institutional Transactions XNCR Stock Analysis - Frequently Asked Questions Should I buy or sell Xencor stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XNCR shares. View XNCR analyst ratings or view top-rated stocks. What is Xencor's stock price target for 2024? 9 brokerages have issued 1 year price targets for Xencor's stock. Their XNCR share price targets range from $24.00 to $50.00. On average, they predict the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 90.0% from the stock's current price. View analysts price targets for XNCR or view top-rated stocks among Wall Street analysts. How have XNCR shares performed in 2024? Xencor's stock was trading at $21.23 at the beginning of 2024. Since then, XNCR shares have decreased by 10.7% and is now trading at $18.95. View the best growth stocks for 2024 here. When is Xencor's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our XNCR earnings forecast. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by $0.67. The biopharmaceutical company had revenue of $44.70 million for the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative net margin of 74.90% and a negative trailing twelve-month return on equity of 18.67%. The firm's revenue for the quarter was up 106.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.20) EPS. What ETFs hold Xencor's stock? ETFs with the largest weight of Xencor (NASDAQ:XNCR) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Genomics Immunology and Healthcare ETF (IDNA).ALPS Medical Breakthroughs ETF (SBIO). What is Bassil I. Dahiyat's approval rating as Xencor's CEO? 6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN). Who are Xencor's major shareholders? Xencor's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.02%), Los Angeles Capital Management LLC (0.02%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Celia Eckert, John J Kuch, John R Desjarlais and Kurt A Gustafson. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XNCR) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving TrendsHow Biden has already won 2024Porter & CompanyTop 5 Tech Stocks to Buy for 2024Daily Market AlertsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.